Transcription of ANNUAL REPORT 2017 - viforpharma.com
{{id}} {{{paragraph}}}
ANNUAL . REPORT . 2017 . ANNUAL REPORT 2017 . AT A GLANCE. Guidance raised at half-year, continued good performance in H2. led to strong full-year results Net sales CHF 1, million, up on a constant currency basis EBITDA CHF million, up excluding Veltassa launch costs Cash net of debt of CHF million Transformation into a pure-play pharmaceutical company successfully completed Separation of Galenica Sant via initial public offering (IPO). Etienne Jornod re-elected as Executive Chairman with remuneration exclusively in shares blocked until 2020.
Vifor Pharma Ltd. Annual Report 2017 7 172 We are extremely proud of our employees’ outstanding achievements in 2017 and we are grateful for their efforts to ensure a strong
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}